Avid Bioservices Signs Manufacturing Supply Agreement For Production Of Monoclonal Antibodies

04-Nov-2003

Avid Bioservices, Inc., a wholly-owned subsidiary of Peregrine Pharmaceuticals , announced that it has signed an agreement with an undisclosed biotechnology company for the cGMP manufacture of monoclonal antibodies to be used in upcoming clinical studies.

"We are pleased Avid was chosen to manufacture this new therapeutic monoclonal antibody," said Jay Treat, Ph.D., Avid's vice president of business development. "This is a comprehensive project in which Avid will take the client's cell line from cell bank production through process scale-up to delivery of vialed cGMP manufactured material for clinical trials. Avid will also provide full regulatory support by preparing the Chemistry, Manufacturing and Controls (CMC) section of the client's Investigational New Drug (IND) application to enable them to advance into human clinical trials."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous